{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:32:05Z","timestamp":1791228725395,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ekir.2026.106545","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:13:15Z","timestamp":1776323595000},"page":"106545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-Hoc Analysis on the Effects of Vicadrostat\/Empagliflozin by CKD Severity\/Hypertension Status"],"prefix":"10.1016","volume":"11","author":[{"given":"Ricardo","family":"Correa-Rotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Canziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza","family":"Caramori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Meyerhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Urbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimoli V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106545_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213749","article-title":"Sodium-glucose cotransporter-2 inhibitors-miracle drugs for the treatment of chronic kidney disease irrespective of the diabetes status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials","volume":"23","author":"Gohda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106545_bib2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106545_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106545_bib4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106545_bib5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2021.5469","article-title":"The leading causes of death in the US for 2020","volume":"325","author":"Ahmad","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106545_bib6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106545_bib7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106545_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101068","article-title":"Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review","volume":"14","author":"Alshahrani","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2026.106545_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2015.05.125","article-title":"The renal effects of mineralocorticoid receptor antagonists","volume":"200","author":"Bianchi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ekir.2026.106545_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2026.106545_bib11","article-title":"Aldosterone antagonists for people with chronic kidney disease requiring dialysis","volume":"2","author":"Hasegawa","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2026.106545_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73638-4","article-title":"The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"10","author":"Minakuchi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106545_bib13","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106545_bib14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106545_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106545_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000534808","article-title":"Methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease","volume":"55","author":"Tuttle","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106545_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106545_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106545_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12882-020-02151-7","article-title":"The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis","volume":"21","author":"Weldegiorgis","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106545_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/j.ajkd.2025.11.009","article-title":"Cumulative effects of vicadrostat and empagliflozin on albuminuria in CKD","volume":"87","author":"Rossing","year":"2026","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106545_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106545_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106545_bib24","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2026.106545_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S2213-8587(25)00222-0","article-title":"Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis","volume":"13","author":"Herrington","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106545_bib29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ejhf.2220","article-title":"Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial","volume":"23","author":"Pellicori","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2026.106545_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106545_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib33","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib34","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106545_bib35","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106545_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:01:55Z","timestamp":1784577715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2468024926027774"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106545","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Hoc Analysis on the Effects of Vicadrostat\/Empagliflozin by CKD Severity\/Hypertension Status","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106545"}}